Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study

• DOI: 10.1016/j.ejca.2025.115409
• Publication Date: 2025-04-06T23:21:34Z
• Authors: Pietro De Placido; Rossana Di Rienzo; Erica Pietroluongo; Claudia Martinelli; Margherita Tafuro; Pietro Formisano; Vittoria D’Esposito; Francesca Benedet...; Tommaso Ruelle; Barbara Cardinali; Vincenzo Di Lauro; Giuseppe Buono; Roberta Caputo; Roberto Buonaiuto; Aldo Caltavituro; Paola Rocco; Giuseppe Porciello; Michelino De Laur...; Lucia Del Mastro; Claudio Vernieri; Bianca Maria Vene...; Roberto Bianco; Anna Crispo; Carmine De Angelis; Grazia Arpino; Mario Giuliano
• Keywords: Association (psychology)

Hormone receptor-positive (HR+)/HER2-negative (HER2-) early-stage breast cancers (EBC) are treated with adjuvant endocrine therapy (ET), chemotherapy (CT) reserved for high-risk cases. Obesity is linked to increased recurrence risk. The Oncotype DX® assay predicts prognosis and CT benefit. PRO BONO study evaluated DX test's impact on treatment decisions explored associations between genomic risk, tumor features, patient metabolic profiles. Patients HR+ /HER2-EBC undergoing testing were enrolled. Body mass index (BMI), characteristics (ER, PR, Ki67, grading, size, nodal status), a large panel of analytes, Recurrence Score® (RS) results collected. Treatment recommendations (ET vs CT-ET) recorded pre- post-Oncotype DX, concordance was determined using Cohen's Kappa. Associations tested Chi-Square test Spearman Correlation. Of the 248 EBC patients (2019-2021), reduced use by 47.7 %. Higher RS positively correlated serum triglycerides inversely GIP (all p < 0.05). No significant association found BMI result. Conversely, size (p = 0.0286) levels leptin 0.0079), PAI-1 0.0083), C-peptide 0.0124), 0.0036), GLP-1 0.0476), glucagon 0.0224), insulin 0.0327). A BMI≥ 30 higher (>148.85pg/ml) independently associated odds having larger (>2 cm). Score result significantly impacts in /HER2-EBC. not BMI, although unfavorable profiles obesity-related markers tumors. These findings highlight need further investigate link cancer biology.